A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers

Part of paid clinical trials in Bedminster, New Jersey.

Sponsor
Aerie Pharmaceuticals
Study ID
NCT02406287
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Subjects

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Netarsudil (AR-13324) Ophthalmic Solution — DRUG
    Topical ophthalmic solution
  • Netarsudil (AR-13324) Ophthalmic Solution Placebo — DRUG
    Ophthalmic solution once a day

Study Details

To evaluate the effect of netarsudil (AR-13324) ophthalmic solution on aqueous humor dynamics relative to its placebo.

Key Dates

Start date
Apr 30, 2015
Status verified
Sep 2016
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016

Study Design

Enrollment
10 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Active
    Netarsudil (AR-13324) Ophthalmic Solution
  • Placebo Comparator: Placebo
    Netarsudil (AR-13324) Ophthalmic Solution Placebo

Primary Outcome Measure

Change in aqueous humor flow rate measured by non-contact fluorophotometer [ Time Frame: Day 1 compared to Day 8 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Aerie PharmaceuticalBedminsterNew Jersey07921-

Find similar trials in Bedminster, NJ

By research site
Aerie Pharmaceutical· Bedminster, NJ

Related Studies